This company is a clinical-stage biopharmaceutical business focused on developing its lead clinical candidate, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, for the treatment of hypertension and other cardio-renal diseases.
Crazy to think 1yr to the post ConCor are being bought by AZ!